Easton Pharmaceuticals Inc (OTCMKTS:EAPH) has finalized a LOI for the purchase of revenue producing therapeutics firm, Herbs of Kedem. The company has sales in surplus of $2.2 million and healthy profit margins with an existing net profit of almost $1.5 million with minimal marketing coverage.

The highlights

Herbs of Kedem presently has 10 adult anti-aging and skin care offerings, 5 hair loss and hair care offerings, 4 nail care and foot items, 16 skin care items, 6 respiratory tract treatment offerings and 4 food supplement items. The company’s therapeutic natural offerings with its key ingredients being obtained from the Dead Sea and with supply channels via numerous European and recently finalized North American suppliers, Easton considers the revenue capabilities of these offerings can expand considerably as the quality is unparalleled.

Most of the offerings comprising its hair restoration product to cure male pattern baldness have witnessed clinical studies. Easton projects to soon report testing and sales assessments of certain products in selected outlets at a Canadian Retail Pharmacy Chain with more than 1,253 sites in Canada. Additional updates on the planned purchase of Herbs Of Kadem will be reported as and when available.

This potential deal would be considered as the second recent purchase by Easton Pharmaceuticals of a revenue producing firm subsequent the closing of iBliss, Inc. and its consumer health products and vaporizer.

Easton is a diversified specialty pharma firm involved in different pharmaceutical sectors and other expanding industries. It first advanced and owned wound-healing drug and presently owns topically delivered medications to cure cancer and other therapeutic products targeting various conditions. All these drugs are in different phases of development and approval.

The company has associated with BMV Medica SA de C.V. to own the exceptional distribution rights in Latin America and Mexico for patented women’s preventative and diagnostic care offerings from Common Sense Of Israel.